Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SL77.0499-10 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SL77.0499-10 (alfuzosin hydrochloride) | DRUG | - |
Inclusion Criteria: * suffering from LUTS related to BPH for at least 6 months; * having an IPSS \>13; * having a urinary peak flow rate 5.0 to 12.0 mL/s for a voided volume of at least 150 mL; * having a residual urine volume \< or = 200 mL.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Boston Scientific Corporation | BSX | 2 | - | Undisclosed |
| PROCEPT BioRobotics Corp. | PRCT | 2 | N/A | Undisclosed |
| EDAP TMS SA Sponsored ADR | EDAP | 1 | N/A | Undisclosed |
| Profound Medical Corp | PROF | 1 | - | Undisclosed |
SL77.0499-10 is an investigational small molecule being developed for benign prostatic hyperplasia (BPH), a condition that causes lower urinary tract symptoms. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
SL77.0499-10 is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 2 clinical trials for benign prostatic hyperplasia.
SL77.0499-10 is in Phase 2 clinical development. It is an investigational drug for benign prostatic hyperplasia and has not been approved for commercial use. One Phase 2 trial has been completed.
SL77.0499-10 has one completed clinical trial, NCT00409357, a Phase 2 dose-ranging study in patients with lower urinary tract symptoms related to benign prostatic hyperplasia. The trial enrolled 473 male participants aged 50 years and older in Japan.
SL77.0499-10 is not the same as alfuzosin. The completed clinical trial NCT00409357 was a dose-ranging study of alfuzosin, not SL77.0499-10. SL77.0499-10 is a separate investigational drug being developed by Sanofi for benign prostatic hyperplasia.